Sequential treatment with a TNFR2 agonist and a TNFR1 antagonist improves outcomes in a humanized mouse model for MS
Authors:
- Valentina PegorettiVPValentina Pegoretti
- Jan BauerJBJan Bauer
- Roman FischerRFRoman Fischer
- Iskra ParoIPIskra Paro
- Wanda DouwengaWDWanda Douwenga
- Roland E. KontermannRKRoland E. Kontermann
- Klaus PfizenmaierKPKlaus Pfizenmaier
- Evelien HoubenEHEvelien Houben
- Bieke BrouxBBBieke Broux
- Niels HellingsNHNiels Hellings
- Wia BaronWBWia Baron
- Jon D. LamanJLJon D. Laman
Open Access
- 3 May 2023
- journal article
- research article
- Published by Springer Nature in Journal of Neuroinflammation
- Vol. 20 (1) , 1-13
Abstract
TNF signaling is an essential regulator of cellular homeostasis. Through its two receptors TNFR1 and TNFR2, soluble versus membrane-bound TNF enable cell death or survival in a variety of cell types. TNF-TNFRs signaling orchestrates important biological functions such as inflammation, neuronal activity as well as tissue de- and regeneration. TNF-TNFRs signaling is a therapeutic target for neurodegenerative diseases such as multiple sclerosis (MS) and Alzheimer’s disease (AD), but animal and clinical studies yielded conflicting findings. Here, we ask whether a sequential modulation of TNFR1 and TNFR2 signaling is beneficial in experimental autoimmune encephalomyelitis (EAE), an experimental mouse model that recapitulates inflammatory and demyelinating aspects of MS. To this end, human TNFR1 antagonist and TNFR2 agonist were administered peripherally at different stages of disease development in TNFR-humanized mice. We found that stimulating TNFR2 before onset of symptoms leads to improved response to anti-TNFR1 therapeutic treatment. This sequential treatment was more effective in decreasing paralysis symptoms and demyelination, when compared to single treatments. Interestingly, the frequency of the different immune cell subsets is unaffected by TNFR modulation. Nevertheless, treatment with only a TNFR1 antagonist increases T-cell infiltration in the central nervous system (CNS) and B-cell cuffing at the perivascular sites, whereas a TNFR2 agonist promotes Treg CNS accumulation. Our findings highlight the complicated nature of TNF signaling which requires a timely balance of selective activation and inhibition of TNFRs in order to exert therapeutic effects in the context of CNS autoimmunity.Keywords
Funding Information
- Stichting MS Research (15-898 MS)
- Resano
- Baliopharm
- Belgian Charcot Foundation
- Fonds voor Wetenschappelijk Onderzoek
This publication has 59 references indexed in Scilit:
- Inhibition of soluble tumour necrosis factor is therapeutic in experimental autoimmune encephalomyelitis and promotes axon preservation and remyelinationBrain, 2011
- The relevance of animal models in multiple sclerosis researchPathophysiology, 2011
- Activation of TNF receptor 2 in microglia promotes induction of anti-inflammatory pathwaysMolecular and Cellular Neuroscience, 2010
- Tumor Necrosis Factor (TNF)-mediated Neuroprotection against Glutamate-induced Excitotoxicity Is Enhanced by N-Methyl-D-aspartate Receptor ActivationJournal of Biological Chemistry, 2004
- Induction of TNF Receptor I-Mediated Apoptosis via Two Sequential Signaling ComplexesCell, 2003
- Tumor necrosis factor signalingCell Death & Differentiation, 2003
- TNF neutralization in MSNeurology, 1999
- The transmembrane form of tumor necrosis factor is the prime activating ligand of the 80 kDa tumor necrosis factor receptorCell, 1995
- Differential Oligodendroglial Expression of the Tumor Necrosis Factor Receptors In Vivo and In VitroJournal of Neurochemistry, 1995
- Two types of TNF receptors are expressed on human normal and malignant B lymphocytesClinical Immunology and Immunopathology, 1991